Biohaven Announces Expanded Patient Access to Nurtec® ODT (rimegepant), Achieving Best-in-Class Commercial Insurance Coverage and Label Update

/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced two updates regarding Nurtec® ODT (rimegepant), the only FDA-approved...

Related Keywords

United States ,America ,Chris Barrett ,Jennifer Porcelli ,Mike Beyer ,Biohaven Neuroinnovation ,World Health Organization ,Drug Administration ,Sam Brown Inc ,Exchange Commission ,Government Affairs ,Biohaven Pharmaceutical Holding Company Ltd ,Pfizer Inc ,European Union ,Academy Of Breastfeeding Medicine ,Prnewswire Biohaven Pharmaceutical Holding Company Ltd ,Commercial Lives ,Lives Covered ,Lactation Data ,Patient Information ,Pharmaceutical Holding Company ,Broader Commercial Insurance ,Managed Markets ,Include Data ,Specific Populations ,Elyse Stock ,Chief Medical ,Breastfeeding Medicine ,Medicinal Products ,Human Use ,European Medicines Agency ,Prescribing Information ,Channel Activators ,Looking Statements ,Private Securities Litigation Reform Act ,Annual Report ,Biohaven Pharmaceutical Ireland ,Biohaven Pharmaceutical Holding Company ,Investor Relations ,Global Burden ,Disease Study ,Lancet Neurol ,